Auxiliary diagnosis of Lung Cancer on the basis of a Serum Protein Biomarker Panel.

Abstract

Objectives: In this study, we established a serum protein biomarker panel (consisting of Pro-SFTPB, CA125, Cyfra21-1, and CEA) and evaluated the feasibility and performance for the auxiliary diagnosis of lung cancer in the Chinese population. Materials and Methods: The current study was a single-center study based on the Chinese population and performed in two cohorts (training cohort and validation cohort). Serum concentrations of Pro-SFTPB, CA125, Cyfra21-1, and CEA were measured by a bead-based flow fluorescence immunoassay. The discrimination performance of the model was assessed using sensitivity, specificity, and the area under the receiver operating characteristic (ROC) curve (AUC). Results: For the biomarker panel model, the AUC was 0.88 (95% CI, 0.85-0.91) in the training cohort and 0.90 (95% CI, 0.86-0.92) in the validation data cohort, which was significantly greater than the AUC of each biomarker alone. For the nodule risk model, the AUC was improved to 0.96 (95% CI, 0.94-0.98) in the training cohort and 0.95 (95% CI, 0.93-0.97) in the validation cohort. In addition, the biomarker panel model yielded an AUC of 0.78 (95% CI, 0.74-0.81) for stage I & II lung cancer, better than the performance of individual biomarker alone. Conclusions: It was demonstrated that 4-protein biomarker panel had a significant performance in identifying lung cancer patients from healthy controls, especially combining with the nodule size. Specifically, it yielded excellent discrimination for identifying early-stage lung cancer patients than individual biomarker alone. A future large-scale study is underway to further define the clinical application of this method for the early diagnosis of lung cancer among Chinese populations.

• Authors: Qiong Lu, Zhongwei Jia, Junli Gao, Meijuan Zheng, Junshun Gao, Mingjie Tong, Jinxing Xia, Fang Li, Baoling Yang, Lili Zhang, Bo Wang, Rui Wang, Jinping Qiao, Qinqin Lou, Jinbo Gao, Yuanhong Xu
• Journal: Journal of Cancer (J Cancer) Vol. 12 Issue 10 Pg. 2835-2843 ( 2021) ISSN: 1837-9664 [Print] Australia
• PMID: 33854584 (Publication Type: Journal Article)
• Copyright: © The author(s).